[HTML][HTML] Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - Trials, 2021 - Springer
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
[PDF][PDF] Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - 2021 - pure.eur.nl
Background: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …
[PDF][PDF] Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - 2021 - repository.ubn.ru.nl
BACKGROUND: The BULLSEYE trial is a multicenter, open-label, randomized controlled
trial to test the hypothesis if (177) Lu-PSMA is an effective treatment in oligometastatic …
trial to test the hypothesis if (177) Lu-PSMA is an effective treatment in oligometastatic …
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - 2021 - pubmed.ncbi.nlm.nih.gov
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
[HTML][HTML] Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort… - …, 2021 - trialsjournal.biomedcentral.com
The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the
hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive …
hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive …
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - Trials, 2021 - search.proquest.com
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
[PDF][PDF] Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - 2021 - scholar.archive.org
Background: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - Trials, 2021 - go.gale.com
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if. sup. 177Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if. sup. 177Lu-PSMA is an effective treatment in oligometastatic hormone …
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
BM Privé, MJR Janssen, IM van Oort, CHJ Muselaers… - Trials, 2021 - europepmc.org
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
BM Privé, MJR Janssen, IM van Oort… - …, 2021 - researchinformation.amsterdamumc …
Background: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …
test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone …